Table 2. Estimated drug-related revenue... | American Society of Hematology

Table 2.

Estimated drug-related revenue for first-line classic Hodgkin lymphoma treatment administered in the US outpatient setting

First-line regimen	Drug expenses, per 6 cycles (USD)	Drug revenue per 6 cycles, non–340B Drug Discount Program * (USD)	Drug revenue per 6 cycles, 340B Drug Discount Program† (USD)
ABVD	1663.02	71.50	565.43
BV + AVD	203 006.52	8729.28	69 022.22

First-line regimen	Drug expenses, per 6 cycles (USD)	Drug revenue per 6 cycles, non–340B Drug Discount Program * (USD)	Drug revenue per 6 cycles, 340B Drug Discount Program† (USD)
ABVD	1663.02	71.50	565.43
BV + AVD	203 006.52	8729.28	69 022.22

ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; BV + AVD, brentuximab vedotin with doxorubicin, vinblastine, dacarbazine.

Current Medicare reimbursement is equal to average sales price + 4.3%.

340B Drug Discount Program discount estimated at 34% of average sales price.